Akebia Therapeutics Inc.
10/16/2024 | Press release | Distributed by Public on 10/16/2024 05:37
Material Agreement Form 8 K
Item 1.01. Entry into a Material Definitive Agreement.
As previously disclosed, on February 10, 2021, Akebia Therapeutics, Inc. (the "Company") entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation ("STA") (the "Supply Agreement"), under which STA manufactures vadadustat drug product ("Product") for the Company.
On October 15, 2024, the Company and STA entered into Amendment #1 to the Supply Agreement (the "Amendment"). Pursuant to the Amendment, the term of the Supply Agreement is extended until January 1, 2032. In addition, the Amendment amends the volume-based pricing structure and certain other provisions related to the Product under the Supply Agreement.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.